Venous thromboembolism prophylaxis and treatment with enoxaparin (Clexane)
Enoxaparin is a low-molecular-weight heparin used for inpatient VTE thromboprophylaxis and for therapeutic anticoagulation in acute DVT with or without PE. [1] Therapeutic anticoagulation is administered by subcutaneous injection at weight-based dosing regimens, with renal impairment dose reduction. [2]
Indications for enoxaparin initiation
Enoxaparin thromboprophylaxis is indicated for patients undergoing abdominal surgery at risk for thromboembolic complications, for hip or knee replacement surgery, and for medical patients with severely restricted mobility during acute illness. [2] Enoxaparin therapeutic anticoagulation is indicated for inpatient treatment of acute DVT with or without PE when administered in conjunction with warfarin, and for outpatient treatment of acute DVT without PE when administered in conjunction with warfarin. [2] For acutely ill hospitalized medical patients at increased thrombosis risk, anticoagulant thromboprophylaxis with LMWH is recommended. [3] Extended-duration thromboprophylaxis beyond the acute hospital stay is suggested against in most acutely ill medical patients. [3]
Administration technique and standard routes
Enoxaparin is administered by subcutaneous injection. [2] For thromboprophylaxis and therapeutic regimens described in the prescribing information, dosing is given at fixed daily or q12h intervals by subcutaneous administration. [2]
Thromboprophylaxis dosing (when and how)
Medical (non-surgical) patients with acute illness and restricted mobility
For medical patients at risk due to severely restricted mobility during acute illness, the prophylactic dose is 40 mg subcutaneously once daily. [2] The usual duration for medical prophylaxis is 6 to 11 days. [2]
Abdominal surgery prophylaxis
For abdominal surgery prophylaxis, the recommended dose is 40 mg subcutaneously once daily. [2] The initial dose is given 2 hours prior to surgery. [2] The usual duration is 7 to 10 days. [2]
Hip or knee replacement surgery prophylaxis
For hip or knee replacement surgery prophylaxis, the recommended dose is 30 mg subcutaneously every 12 hours. [2] The initial dose is administered 12 to 24 hours after surgery, provided that hemostasis has been established. [2] The usual duration is 7 to 10 days. [2]
Alternate hip replacement prophylaxis regimen in labeling
For hip replacement surgery, a prophylaxis dose of 40 mg subcutaneously once daily may be considered for up to 3 weeks. [2] The initial dose is administered 12 (±3) hours prior to surgery. [2]
Therapeutic anticoagulation dosing (acute DVT with or without PE)
Outpatient acute DVT without PE regimen
For outpatient treatment of acute DVT without PE when administered in conjunction with warfarin, the recommended dose is 1 mg/kg subcutaneously every 12 hours. [2]
Inpatient acute DVT with PE or acute DVT without PE not eligible for outpatient treatment
For inpatient treatment of acute DVT with PE or acute DVT without PE not eligible for outpatient treatment when administered in conjunction with warfarin, the recommended dose is 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily. [2]
Warfarin overlap and continuation duration in labeling
In both outpatient and inpatient (hospital) treatments, warfarin is initiated when appropriate, usually within 72 hours of enoxaparin. [2] Enoxaparin is continued for a minimum of 5 days and until a therapeutic oral anticoagulant effect is achieved (INR 2 to 3). [2] The average duration of enoxaparin administration is 7 days. [2]
Patient selection and initiation safety checks
Bleeding risk evaluation is recommended prior to starting enoxaparin unless treatment is urgently needed. [2] Renal function should be assessed because severe renal impairment requires prophylaxis and treatment dose reduction. [2]
Renal impairment dosing for prophylaxis and treatment
For severe renal impairment (creatinine clearance <30 mL/min), prophylaxis dosing is reduced to 30 mg subcutaneously once daily for abdominal surgery, hip or knee replacement surgery, and medical patients during acute illness. [2] For severe renal impairment (creatinine clearance <30 mL/min), inpatient treatment of acute DVT with or without PE is reduced to 1 mg/kg subcutaneously once daily. [2]
Surgical timing nuances affecting “when” the first dose is given
For abdominal surgery prophylaxis, the initial enoxaparin dose is administered 2 hours prior to surgery. [2] For hip or knee replacement surgery prophylaxis using the 30 mg q12h regimen, the first dose is administered 12 to 24 hours after surgery when hemostasis is established. [2] For prophylaxis with the 40 mg once-daily hip replacement regimen, the initial dose is administered 12 (±3) hours prior to surgery. [2]
Key practice constraints and common administration errors
Neuraxial anesthesia timing should be addressed because enoxaparin use for thromboprophylaxis or anticoagulation requires consideration of bleeding risk around neuraxial interventions. [2] Dose timing should follow the specific regimen labeling because prophylaxis initiation windows differ by surgical type (2 hours before abdominal surgery versus 12–24 hours after hip/knee surgery versus 12±3 hours before hip replacement in the alternate regimen). [2] Therapeutic dosing should remain weight-based because dosing is prescribed as fixed weight-based mg/kg regimens (1 mg/kg q12h, 1.5 mg/kg daily, or reduced 1 mg/kg daily in severe renal impairment). [2]